New US patent granted covering Histotype Px®
OSLO – May 7, 2026 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine for cancer, is pleased to announce that US patent 12,591,973 has been granted by the US Patent and Trademark Office (USPTO).
The newly granted patent is a second continuation of US patent 11,361,442 and provides important protection of the novel methods and technology underpinning DoMore Diagnostics' digital AI biomarkers. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
Torbjørn Furuseth MD, Co-Founder and CEO at DoMore Diagnostics, commented
"This grant is another meaningful step in expanding the protection of our IP on the Histotype Px platform in the United States. The patents further strengthens our position as a leader in the field of AI-based outcome prediction and treatment decision support, and underscores the novelty of the science developed together with Oslo University Hospital. We remain firmly committed to pursuing broad and durable IP coverage as we continue to lead in AI-based outcome prediction for cancer patients."
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.comLinkedInThe Lancet publication The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD torbjorn.furuseth@domorediagnostics.com